{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T10:12:42Z","timestamp":1788862362152,"version":"build-2803163510"},"reference-count":40,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100017594","name":"Medical Science and Technology Project of Zhejiang Province","doi-asserted-by":"publisher","award":["2021KY580"],"award-info":[{"award-number":["2021KY580"]}],"id":[{"id":"10.13039\/501100017594","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["obgyn.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Obstet and Gynaecol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of pamiparib monotherapy in recurrent ovarian cancer (rOC) after prior PARPi exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a prospective clinical trial. Fifteen patients were enrolled between August 2022 and December 2023. Oral pamiparib 60\u2009mg twice daily was administered until conditions specified in the protocol. Primary endpoint was clinical benefit rate \u2265\u20094\u2009months (CBR4m; percentage of patients who sustained complete response, partial response [PR], and stable disease for at least 4\u2009months). Secondary endpoints included progression\u2010free survival (PFS), overall response rate (ORR), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Median number of previous treatment line was 3 (range, 2\u20136). CBR4m was 26.7% and the study was halted in the first stage according to the pre\u2010set statistical criteria. Two patients achieved PR for an ORR of 13.3%. With a median follow\u2010up of 16.1\u2009months, median PFS and OS were respectively 2.8 (95% confidence interval [CI], 1.6\u2013NR) and 15.6 (95% CI, 8.4\u2013NR) months. Subgroup analyses showed CBR4m of 37.5% (3\/8) in BRCAmut and 14.3% (1\/7) in BRCAwt cohorts. CA\u2010125 response according to GCIG criteria was observed in 26.7% of patients. There were no treatment\u2010related serious adverse events or deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Pamiparib monotherapy preliminarily showed limited efficacy and acceptable safety profiles in heavily pretreated rOC after prior PARPi exposure. The results suggested that single\u2010agent pamiparib retreatment may not be an effective treatment for this patient population; further investigation of combining PARPi with agents with different mechanisms may be warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jog.70292","type":"journal-article","created":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T06:49:46Z","timestamp":1777445386000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Pamiparib Monotherapy in Recurrent Ovarian Cancer After Prior\n                    <scp>PARPi<\/scp>\n                    Exposure: A Prospective, Open\u2010Label, Single\u2010Arm, Phase\n                    <scp>II<\/scp>\n                    Study"],"prefix":"10.1111","volume":"52","author":[{"given":"Feng","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4833-5996","authenticated-orcid":false,"given":"Guangyi","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5736-7397","authenticated-orcid":false,"given":"Jianqing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM) Chinese Academy of Sciences  Zhejiang Hangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,28]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19138113"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1456"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611310"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32440-6"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30469-2"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909707"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01003"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1810858"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30029-4"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01549"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells13221847"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00532-x"},{"key":"e_1_2_14_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.3110"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2022.100939"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100699"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188633"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09312-9"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01934-0"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23952"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep12670"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2021.08.007"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx367.003"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3575"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2020.06.009"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c01346"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1186"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-5338"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182070f17"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(02)00091-4"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105535"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061607"},{"key":"e_1_2_14_35_1","volume-title":"Evolve: A Post PARP Inhibitor Clinical Translational Phase II Trial of Cediranib\u2010Olaparib in Ovarian Cancer\u2014A Princess Margaret Consortium\u2013GCIG Phase II Trial","author":"Lheureux S.","year":"2019"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19148577"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70391-2"},{"key":"e_1_2_14_38_1","volume-title":"Final Survival Analysis of NSGO\u2010AVANOVA2\/ENGOT\u2010OV24: Combination of Niraparib and Bevacizumab Versus Niraparib Alone as Treatment of Recurrent Platinum\u2010Sensitive Ovarian Cancer\u2014A Randomized Controlled Chemotherapy\u2010Free Study","author":"Mirza M. R.","year":"2020"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.07.433"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-1003"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03917-2"}],"container-title":["Journal of Obstetrics and Gynaecology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.70292","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jog.70292","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jog.70292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T09:31:04Z","timestamp":1788859864000},"score":1,"resource":{"primary":{"URL":"https:\/\/obgyn.onlinelibrary.wiley.com\/doi\/10.1111\/jog.70292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,28]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1111\/jog.70292"],"URL":"https:\/\/doi.org\/10.1111\/jog.70292","archive":["Portico"],"relation":{},"ISSN":["1341-8076","1447-0756"],"issn-type":[{"value":"1341-8076","type":"print"},{"value":"1447-0756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,28]]},"assertion":[{"value":"2025-08-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70292"}}